Hodgkin-limfóma: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• CD20 2
• CD19 11
• PD-1 9
• CD30 9
• PD-L1 2
• BCL-2 2
• STAT3 0
• CD47 1
• JAK 1
• MYC 2
• TP53 0
• ALK 0
• BTK 1
• CD22 0
• IL-6 0
• AKT 0
• CTLA-4 0
• mTOR 0
• PI3K 0
• PRMT5 1
• ABL1 0
• BCMA 0
• CD123 1
• CD38 0
• EZH2 0
• METTL3 0
• NOTCH1 0
• NRF2 0
• TIM-3 0
• AMPK 0
• AXL 0
• BDNF 1
• CCR5 0
• CDK4/6 0
• CXCR4 0
• FGFR 0
• FLT3 0
• GLP-1 0
• HDAC 0
• IL-15 1
• IL-17 0
• MET 0
• MMP-9 0
• NLRP3 0
• PARP 0
• PRAME 0
• SGLT2 0
• SIRT1 0
• TERT 0
• TIGIT 0
• TLR4 0
• TNF 0

37+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  SMART-SMAPs: a new paradigm of cell-free cytotoxic immunotherapy for resistant CLL

  Universita Degli Studi di Siena· Siena, Olaszország· EU contribution 150 000 EUR· until 2028. márc.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the Interplay of Natural Killer Cells and Microbiome in Non-Hodgkin's Lymphoma (LINK-M)

  Luxembourg Institute of Health· Strassen, Luxemburg· EU contribution 216 240 EUR· until 2028. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Integrated Assessment of Indoor Radon and Hazardous Air Pollutants in Non-Hodgkin Lymphoma – a Case-Control Study in a Radon-Prone Area (AlphaLymph)

  Universidad de Santiago de Compostela· Santiago De Compostela, Spanyolország· EU contribution 242 593 EUR· until 2029. febr.· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Studying the Microenvironment And Related Targets in Non-Hodgkin's Lymphoma (SMART-NHL)

  Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer· Barcelona, Spanyolország· EU contribution 181 153 EUR· until 2027. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Development and characterization of a novel CAR T-cell therapy for NHL (CARLY)

  Fundacio Institut de Recerca Contra la Leucemia Josep Carreras· Badalona, Spanyolország· EU contribution 226 441 EUR· until 2027. jún.

5 of 8 running projects, newest first. Listed amounts together: 11,1 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

  NCT03598608· Merck Sharp & Dohme LLC· Frissítve: 2026. júl. 28.

  “Business Reason”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma

  NCT04373083· Regeneron Pharmaceuticals· Frissítve: 2021. jan. 15.

  “Business Decision”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

  NCT03407144· Merck Sharp & Dohme LLC· Forrás

• A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

  NCT04875195· Merck Sharp & Dohme LLC· Forrás

• A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

  NCT05508867· Merck Sharp & Dohme LLC· Forrás

• Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

  NCT03598608· Merck Sharp & Dohme LLC· Forrás

• A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

  NCT02332668· Merck Sharp & Dohme LLC· Forrás

• Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)

  NCT02684292· Merck Sharp & Dohme LLC· Forrás

• A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)

  NCT06504394· Merck Sharp & Dohme LLC· Forrás

• Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

  NCT05216835· AstraZeneca· Forrás

• Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

  NCT05008224· Merck Sharp & Dohme LLC· Forrás

• Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

  NCT05595447· Hospital Regional de Alta Especialidad del Bajio· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 5
• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 1
• Gene Expression Profiling 14
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 5
• Metabolomics 1
• Flow Cytometry 9
• Immunohistochemistry 19
• Liquid Biopsy 1
• Circulating Tumor DNA 6
• Xenograft Model Antitumor Assays 20
• Positron-Emission Tomography 21
• Magnetic Resonance Imaging 18
• Machine Learning 11
• Deep Learning 3
• Cohort Studies 30
• Genome-Wide Association Study 7

• Decoding the Heterogeneity of Diffuse Large B-Cell Lymphomas: A Comprehensive Genetic, Transcriptomic, and Phenotypic Profiling of B-Cell Lymphoma Cell Lines.

  Hematol Oncol, 2026. szept.

• Targeted Transcriptomic Profiling Identifies Biomarkers and Molecular Features Associated With Immunotherapy Response in Classic Hodgkin Lymphoma.

  Mod Pathol, 2026. aug.

• Single-cell sequencing uncovers clonal dynamics profiles and therapeutic resistance biomarkers in relapsed and refractory peripheral T-cell lymphoma.

  Front Immunol, 2026. júl.

• Multidimensional Characterization of Tumor-Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes.

  Cancer Discov, 2026. máj.

• Disordered differentiation and cellular senescence in pediatric Hodgkin Reed-Sternberg cells.

  Blood Adv, 2026. ápr.

• E2F Accelerates the Proliferation of B-Cell Non-Hodgkin Lymphomas by Upregulating Cell-Cycle Genes.

  Curr Med Sci, 2026. ápr.

• Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response.

  Blood Cancer J, 2026. ápr.

• Spatial transcriptomics unveils immune cellular ecosystems associated with patient survival in diffuse large B-cell lymphoma.

  Oncoimmunology, 2026. ápr.

• Identification of plasma exosome circRNA as potential novel biomarkers for DLBCL and circrna-miRNA-mRNA network analysis.

  Clin Exp Med, 2026. ápr.

• Machine learning based on clinical and gene expression data assists in survival prediction and treatment optimization for diffuse large B-Cell lymphoma patients.

  Ann Hematol, 2026. febr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.